Selected research
Market Analysis & Forecast
Global Cold Chain Services for Innovative Drug Market Analysis and Forecast 2026-2032
Market perspective
The global Cold Chain Services for Innovative Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Cold Chain Services for Innovative Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Cold Chain Services for Innovative Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Cold Chain Services for Innovative Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Cold Chain Services for Innovative Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Cold Chain Services for Innovative Drug include Marken, World Courier, Cryoport, DTW Logistics, City Express, Shanghai Shengsheng Pharmaceutical Cold Chain Technology, Thermo Fisher, SF Express and Catalent, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Cold Chain Services for Innovative Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Cold Chain Services for Innovative Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Cold Chain Services for Innovative Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Cold Chain Services for Innovative Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Cold Chain Services for Innovative Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Cold Chain Services for Innovative Drug revenue, projected growth trends, production technology, application and end-user industry.
Cold Chain Services for Innovative Drug Segment by Company
Marken
World Courier
Cryoport
DTW Logistics
City Express
Shanghai Shengsheng Pharmaceutical Cold Chain Technology
Thermo Fisher
SF Express
Catalent
CIMC Cold Cloud
Guoyuan Life Sciences Group
Rochin Logistics
Azenta
Saroute
Cold Chain Services for Innovative Drug Segment by Type
International Transportation
Domestic Transportation
Cold Chain Services for Innovative Drug Segment by Application
Pharmaceutical Companies
Hospitals
Laboratories
Others
Cold Chain Services for Innovative Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cold Chain Services for Innovative Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cold Chain Services for Innovative Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cold Chain Services for Innovative Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Cold Chain Services for Innovative Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Cold Chain Services for Innovative Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cold Chain Services for Innovative Drug revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- International Transportation
- Domestic Transportation
Applications
- Pharmaceutical Companies
- Hospitals
- Laboratories
- Others
Companies covered
- Marken
- World Courier
- Cryoport
- DTW Logistics
- City Express
- Shanghai Shengsheng Pharmaceutical Cold Chain Technology
- Thermo Fisher
- SF Express
- Catalent
- CIMC Cold Cloud
- Guoyuan Life Sciences Group
- Rochin Logistics
- Azenta
- Saroute
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Cold Chain Services for Innovative Drug Market by Type
- 1.2.1 Global Cold Chain Services for Innovative Drug Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 International Transportation
- 1.2.3 Domestic Transportation
- 1.3 Cold Chain Services for Innovative Drug Market by Application
- 1.3.1 Global Cold Chain Services for Innovative Drug Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Pharmaceutical Companies
- 1.3.3 Hospitals
- 1.3.4 Laboratories
- 1.3.5 Others
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Cold Chain Services for Innovative Drug Market Dynamics
- 2.1 Cold Chain Services for Innovative Drug Industry Trends
- 2.2 Cold Chain Services for Innovative Drug Industry Drivers
- 2.3 Cold Chain Services for Innovative Drug Industry Opportunities and Challenges
- 2.4 Cold Chain Services for Innovative Drug Industry Restraints
3 Global Growth Perspective
- 3.1 Global Cold Chain Services for Innovative Drug Market Perspective (2021-2032)
- 3.2 Global Cold Chain Services for Innovative Drug Growth Trends by Region
- 3.2.1 Global Cold Chain Services for Innovative Drug Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Cold Chain Services for Innovative Drug Market Size by Region (2021-2026)
- 3.2.3 Global Cold Chain Services for Innovative Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Cold Chain Services for Innovative Drug Revenue by Players
- 4.1.1 Global Cold Chain Services for Innovative Drug Revenue by Players (2021-2026)
- 4.1.2 Global Cold Chain Services for Innovative Drug Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Cold Chain Services for Innovative Drug Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Cold Chain Services for Innovative Drug Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Cold Chain Services for Innovative Drug Key Players Headquarters & Area Served
- 4.4 Global Cold Chain Services for Innovative Drug Players, Product Type & Application
- 4.5 Global Cold Chain Services for Innovative Drug Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Cold Chain Services for Innovative Drug Market CR5 and HHI
- 4.6.3 2025 Cold Chain Services for Innovative Drug Tier 1, Tier 2, and Tier 3
5 Cold Chain Services for Innovative Drug Market Size by Type
- 5.1 Global Cold Chain Services for Innovative Drug Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Cold Chain Services for Innovative Drug Revenue by Type (2021-2032)
- 5.3 Global Cold Chain Services for Innovative Drug Revenue Market Share by Type (2021-2032)
6 Cold Chain Services for Innovative Drug Market Size by Application
- 6.1 Global Cold Chain Services for Innovative Drug Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Cold Chain Services for Innovative Drug Revenue by Application (2021-2032)
- 6.3 Global Cold Chain Services for Innovative Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Marken
- 7.1.1 Marken Company Information
- 7.1.2 Marken Business Overview
- 7.1.3 Marken Cold Chain Services for Innovative Drug Revenue and Gross Margin (2021-2026)
- 7.1.4 Marken Cold Chain Services for Innovative Drug Product Portfolio
- 7.1.5 Marken Recent Developments
- 7.2 World Courier
- 7.2.1 World Courier Company Information
- 7.2.2 World Courier Business Overview
- 7.2.3 World Courier Cold Chain Services for Innovative Drug Revenue and Gross Margin (2021-2026)
- 7.2.4 World Courier Cold Chain Services for Innovative Drug Product Portfolio
- 7.2.5 World Courier Recent Developments
- 7.3 Cryoport
- 7.3.1 Cryoport Company Information
- 7.3.2 Cryoport Business Overview
- 7.3.3 Cryoport Cold Chain Services for Innovative Drug Revenue and Gross Margin (2021-2026)
- 7.3.4 Cryoport Cold Chain Services for Innovative Drug Product Portfolio
- 7.3.5 Cryoport Recent Developments
- 7.4 DTW Logistics
- 7.4.1 DTW Logistics Company Information
- 7.4.2 DTW Logistics Business Overview
- 7.4.3 DTW Logistics Cold Chain Services for Innovative Drug Revenue and Gross Margin (2021-2026)
- 7.4.4 DTW Logistics Cold Chain Services for Innovative Drug Product Portfolio
- 7.4.5 DTW Logistics Recent Developments
- 7.5 City Express
- 7.5.1 City Express Company Information
- 7.5.2 City Express Business Overview
- 7.5.3 City Express Cold Chain Services for Innovative Drug Revenue and Gross Margin (2021-2026)
- 7.5.4 City Express Cold Chain Services for Innovative Drug Product Portfolio
- 7.5.5 City Express Recent Developments
- 7.6 Shanghai Shengsheng Pharmaceutical Cold Chain Technology
- 7.6.1 Shanghai Shengsheng Pharmaceutical Cold Chain Technology Company Information
- 7.6.2 Shanghai Shengsheng Pharmaceutical Cold Chain Technology Business Overview
- 7.6.3 Shanghai Shengsheng Pharmaceutical Cold Chain Technology Cold Chain Services for Innovative Drug Revenue and Gross Margin (2021-2026)
- 7.6.4 Shanghai Shengsheng Pharmaceutical Cold Chain Technology Cold Chain Services for Innovative Drug Product Portfolio
- 7.6.5 Shanghai Shengsheng Pharmaceutical Cold Chain Technology Recent Developments
- 7.7 Thermo Fisher
- 7.7.1 Thermo Fisher Company Information
- 7.7.2 Thermo Fisher Business Overview
- 7.7.3 Thermo Fisher Cold Chain Services for Innovative Drug Revenue and Gross Margin (2021-2026)
- 7.7.4 Thermo Fisher Cold Chain Services for Innovative Drug Product Portfolio
- 7.7.5 Thermo Fisher Recent Developments
- 7.8 SF Express
- 7.8.1 SF Express Company Information
- 7.8.2 SF Express Business Overview
- 7.8.3 SF Express Cold Chain Services for Innovative Drug Revenue and Gross Margin (2021-2026)
- 7.8.4 SF Express Cold Chain Services for Innovative Drug Product Portfolio
- 7.8.5 SF Express Recent Developments
- 7.9 Catalent
- 7.9.1 Catalent Company Information
- 7.9.2 Catalent Business Overview
- 7.9.3 Catalent Cold Chain Services for Innovative Drug Revenue and Gross Margin (2021-2026)
- 7.9.4 Catalent Cold Chain Services for Innovative Drug Product Portfolio
- 7.9.5 Catalent Recent Developments
- 7.10 CIMC Cold Cloud
- 7.10.1 CIMC Cold Cloud Company Information
- 7.10.2 CIMC Cold Cloud Business Overview
- 7.10.3 CIMC Cold Cloud Cold Chain Services for Innovative Drug Revenue and Gross Margin (2021-2026)
- 7.10.4 CIMC Cold Cloud Cold Chain Services for Innovative Drug Product Portfolio
- 7.10.5 CIMC Cold Cloud Recent Developments
- 7.11 Guoyuan Life Sciences Group
- 7.11.1 Guoyuan Life Sciences Group Company Information
- 7.11.2 Guoyuan Life Sciences Group Business Overview
- 7.11.3 Guoyuan Life Sciences Group Cold Chain Services for Innovative Drug Revenue and Gross Margin (2021-2026)
- 7.11.4 Guoyuan Life Sciences Group Cold Chain Services for Innovative Drug Product Portfolio
- 7.11.5 Guoyuan Life Sciences Group Recent Developments
- 7.12 Rochin Logistics
- 7.12.1 Rochin Logistics Company Information
- 7.12.2 Rochin Logistics Business Overview
- 7.12.3 Rochin Logistics Cold Chain Services for Innovative Drug Revenue and Gross Margin (2021-2026)
- 7.12.4 Rochin Logistics Cold Chain Services for Innovative Drug Product Portfolio
- 7.12.5 Rochin Logistics Recent Developments
- 7.13 Azenta
- 7.13.1 Azenta Company Information
- 7.13.2 Azenta Business Overview
- 7.13.3 Azenta Cold Chain Services for Innovative Drug Revenue and Gross Margin (2021-2026)
- 7.13.4 Azenta Cold Chain Services for Innovative Drug Product Portfolio
- 7.13.5 Azenta Recent Developments
- 7.14 Saroute
- 7.14.1 Saroute Company Information
- 7.14.2 Saroute Business Overview
- 7.14.3 Saroute Cold Chain Services for Innovative Drug Revenue and Gross Margin (2021-2026)
- 7.14.4 Saroute Cold Chain Services for Innovative Drug Product Portfolio
- 7.14.5 Saroute Recent Developments
8 North America
- 8.1 North America Cold Chain Services for Innovative Drug Revenue (2021-2032)
- 8.2 North America Cold Chain Services for Innovative Drug Revenue by Type (2021-2032)
- 8.2.1 North America Cold Chain Services for Innovative Drug Revenue by Type (2021-2026)
- 8.2.2 North America Cold Chain Services for Innovative Drug Revenue by Type (2027-2032)
- 8.3 North America Cold Chain Services for Innovative Drug Revenue Share by Type (2021-2032)
- 8.4 North America Cold Chain Services for Innovative Drug Revenue by Application (2021-2032)
- 8.4.1 North America Cold Chain Services for Innovative Drug Revenue by Application (2021-2026)
- 8.4.2 North America Cold Chain Services for Innovative Drug Revenue by Application (2027-2032)
- 8.5 North America Cold Chain Services for Innovative Drug Revenue Share by Application (2021-2032)
- 8.6 North America Cold Chain Services for Innovative Drug Revenue by Country
- 8.6.1 North America Cold Chain Services for Innovative Drug Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Cold Chain Services for Innovative Drug Revenue by Country (2021-2026)
- 8.6.3 North America Cold Chain Services for Innovative Drug Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe Cold Chain Services for Innovative Drug Revenue (2021-2032)
- 9.2 Europe Cold Chain Services for Innovative Drug Revenue by Type (2021-2032)
- 9.2.1 Europe Cold Chain Services for Innovative Drug Revenue by Type (2021-2026)
- 9.2.2 Europe Cold Chain Services for Innovative Drug Revenue by Type (2027-2032)
- 9.3 Europe Cold Chain Services for Innovative Drug Revenue Share by Type (2021-2032)
- 9.4 Europe Cold Chain Services for Innovative Drug Revenue by Application (2021-2032)
- 9.4.1 Europe Cold Chain Services for Innovative Drug Revenue by Application (2021-2026)
- 9.4.2 Europe Cold Chain Services for Innovative Drug Revenue by Application (2027-2032)
- 9.5 Europe Cold Chain Services for Innovative Drug Revenue Share by Application (2021-2032)
- 9.6 Europe Cold Chain Services for Innovative Drug Revenue by Country
- 9.6.1 Europe Cold Chain Services for Innovative Drug Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Cold Chain Services for Innovative Drug Revenue by Country (2021-2026)
- 9.6.3 Europe Cold Chain Services for Innovative Drug Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China Cold Chain Services for Innovative Drug Revenue (2021-2032)
- 10.2 China Cold Chain Services for Innovative Drug Revenue by Type (2021-2032)
- 10.2.1 China Cold Chain Services for Innovative Drug Revenue by Type (2021-2026)
- 10.2.2 China Cold Chain Services for Innovative Drug Revenue by Type (2027-2032)
- 10.3 China Cold Chain Services for Innovative Drug Revenue Share by Type (2021-2032)
- 10.4 China Cold Chain Services for Innovative Drug Revenue by Application (2021-2032)
- 10.4.1 China Cold Chain Services for Innovative Drug Revenue by Application (2021-2026)
- 10.4.2 China Cold Chain Services for Innovative Drug Revenue by Application (2027-2032)
- 10.5 China Cold Chain Services for Innovative Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Cold Chain Services for Innovative Drug Revenue (2021-2032)
- 11.2 Asia Cold Chain Services for Innovative Drug Revenue by Type (2021-2032)
- 11.2.1 Asia Cold Chain Services for Innovative Drug Revenue by Type (2021-2026)
- 11.2.2 Asia Cold Chain Services for Innovative Drug Revenue by Type (2027-2032)
- 11.3 Asia Cold Chain Services for Innovative Drug Revenue Share by Type (2021-2032)
- 11.4 Asia Cold Chain Services for Innovative Drug Revenue by Application (2021-2032)
- 11.4.1 Asia Cold Chain Services for Innovative Drug Revenue by Application (2021-2026)
- 11.4.2 Asia Cold Chain Services for Innovative Drug Revenue by Application (2027-2032)
- 11.5 Asia Cold Chain Services for Innovative Drug Revenue Share by Application (2021-2032)
- 11.6 Asia Cold Chain Services for Innovative Drug Revenue by Country
- 11.6.1 Asia Cold Chain Services for Innovative Drug Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Cold Chain Services for Innovative Drug Revenue by Country (2021-2026)
- 11.6.3 Asia Cold Chain Services for Innovative Drug Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Cold Chain Services for Innovative Drug Revenue (2021-2032)
- 12.2 SAMEA Cold Chain Services for Innovative Drug Revenue by Type (2021-2032)
- 12.2.1 SAMEA Cold Chain Services for Innovative Drug Revenue by Type (2021-2026)
- 12.2.2 SAMEA Cold Chain Services for Innovative Drug Revenue by Type (2027-2032)
- 12.3 SAMEA Cold Chain Services for Innovative Drug Revenue Share by Type (2021-2032)
- 12.4 SAMEA Cold Chain Services for Innovative Drug Revenue by Application (2021-2032)
- 12.4.1 SAMEA Cold Chain Services for Innovative Drug Revenue by Application (2021-2026)
- 12.4.2 SAMEA Cold Chain Services for Innovative Drug Revenue by Application (2027-2032)
- 12.5 SAMEA Cold Chain Services for Innovative Drug Revenue Share by Application (2021-2032)
- 12.6 SAMEA Cold Chain Services for Innovative Drug Revenue by Country
- 12.6.1 SAMEA Cold Chain Services for Innovative Drug Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Cold Chain Services for Innovative Drug Revenue by Country (2021-2026)
- 12.6.3 SAMEA Cold Chain Services for Innovative Drug Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst